CLOs on the Move


 
Embody, Inc. is a commercial-stage company pioneering the next generation regenerative platform for the repair of tendon and ligament injuries with novel collagen-based bio-fabrication techniques and products for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Brianna Schehr
Director of Quality, Regulatory and Clinical Affairs Profile

Similar Companies

Reva Medical

Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage its proprietary biomaterial and stent technologies to improve the treatment of coronary artery disease. Guided by an executive management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA’s initial focus is the development of a drug-eluting bioresorbable coronary scaffold to advance the treatment of cardiovascular disease, the leading cause of death worldwide.

Conceptus, Inc.

Conceptus, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Healthline Med

Healthline Med is a Baldwin Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Laser Dynamics Skin Care Center

Laser Dynamics Skin Care Center is a Lubbock, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

RenalGuard Solutions

Headquartered in Milford, Massachusetts, RenalGuard Solutions, Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard`s effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA. The RenalGuard System™ consists of a closed loop, software-controlled console and single-use sets that physicians and nurses use for automated matched fluid replacement to minimize over- or under-hydration of patients during medical procedures where creating and maintaining high urine outputs is beneficial.